AbbVie Inc (ABBV)vsMedtronic PLC (MDT)
ABBV
AbbVie Inc
$291.27
+1.07%
HEALTHCARE · Cap: $521.11B
MDT
Medtronic PLC
$104.84
-2.90%
HEALTHCARE · Cap: $123.49B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 76% more annual revenue ($66.01B vs $37.54B). ABBV leads profitability with a 15.7% profit margin vs 13.9%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
MDT
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.27
$133.98 premium
Margin of Safety
-2.6%
Fair Value
$94.08
Current Price
$104.84
$10.76 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 40.7% YoY
Generating 1.3B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : MDT
The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : MDT
The primary concerns for MDT are PEG Ratio, Altman Z-Score.
Key Dynamics to Monitor
ABBV profiles as a mature stock while MDT is a value play — different risk/reward profiles.
MDT carries more volatility with a beta of 0.57 — expect wider price swings.
MDT is growing revenue faster at 13.7% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 68/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Medtronic PLC
HEALTHCARE · MEDICAL DEVICES · USA
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?